Ep. 76: Patient-Driven Real World Data – Robert Chu (CEO Embleema)
Robert Chu is the Co-founder & CEO of Embleema. He is the former SVP of Global Technology for IQVIA & has created & managed data networks in over 20 countries in the U.S., Asia & Europe.
Robert and I talk about the tremendous value of provable, secure real world data that can be directly shared by patients to improve bio-statistical models. We also discuss his recent business partnership with Alira Health and the origins of the HIVE data analytics platform.
Embleema Website: https://embleema.com/
Disclaimer: The Health Unchained podcast is for informational and entertainment purposes only and we are not providing any sort of legal, financial, or medical advice. Please do your own research and due diligence before making any important decisions related to these matters.
Topics Overview
•Introduction to Robert’s background
•What drove you to the healthcare industry?
•Experience at IBM, IMS Health, and IQVIA
•How did you first hear about blockchain technology?
•What is the vision for Embleema? Why did you start it?
•Impact of COVID-19 on on Embleema
•Epilepsy Foundation partnership and Epilepsy Digital Engagement Navigator (EDEN)
•Long-term studies are difficult to track
•Why should people care about real world evidence/data?
•Can you describe Embleema’s services/products/platforms and their technology stacks?
•Hyperledger
•HIVE – High Performance Integrated Virtual Environment – data repository and analytics platform built by Dr. Vahan Simonyan who transferred HIVE property to Embleema https://en.wikipedia.org/wiki/High-performance_Integrated_Virtual_Environment
•Tracking patient consent
•What tactics are you employing to address data privacy and personal ownership of one’s data?
•Any feedback from beta-testers of your platform?
•What are the biggest barriers to blockchain adoption in healthcare?
•Synthetic control arms in clinical studies – simulation of placebo group
•Embleema’s business model?
•Company partners and major investors?
•Alira Health Partnership goals
•How would you describe the company culture at Embleema?
•Outlook for 2021 and beyond
•Favorite DLT projects doing important work
•Most influential book you’ve read – The Lorax by Dr. Seuss
•Thoughts about the singularity that is supposed to happen in 2045
•If you had to have micro chip implanted in your body, where would you want it to be implanted?
•Final Takeaways
News Corner
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home
On November 17, 2020, the FDA issued an emergency use authorization for the first COVID-19 diagnostic at-home self-test which provides rapid results. The Lucira COVID-19 All-In-One Test Kit is a molecular (real-time loop mediated amplification reaction) single use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. The Lucira COVID-19 All-In-One Test Kit test has been authorized for home use with self-collected nasal swab samples in individuals age 14 and older who are suspected of COVID-19 by their health care provider.
Health Unchained Links
Website: https://healthunchained.org
Telegram: t.me/healthunchained
Twitter: twitter.com/Healthunchaind
